His primary scientific interests are in Internal medicine, Gastroenterology, Primary sclerosing cholangitis, Primary biliary cirrhosis and Liver disease. His work in Ursodeoxycholic acid, Cirrhosis, Liver transplantation, Liver biopsy and Nonalcoholic fatty liver disease are all subfields of Internal medicine research. His Gastroenterology research incorporates themes from Pathology, Placebo, Biliary cirrhosis and Fatty liver.
His study in Primary sclerosing cholangitis is interdisciplinary in nature, drawing from both Inflammatory bowel disease, Cholangiography, Autoimmune pancreatitis, Retrospective cohort study and Ulcerative colitis. His Primary biliary cirrhosis research focuses on Framingham Risk Score and how it relates to Risk factor and Proportional hazards model. His Liver disease research is multidisciplinary, incorporating perspectives in Steatohepatitis and Weight loss.
Keith D. Lindor mainly focuses on Internal medicine, Gastroenterology, Primary sclerosing cholangitis, Primary biliary cirrhosis and Ursodeoxycholic acid. His Liver transplantation, Cirrhosis, Liver disease and Hepatology study in the realm of Internal medicine connects with subjects such as In patient. His biological study spans a wide range of topics, including Biliary cirrhosis, Surgery and Disease, Pathology.
His Primary sclerosing cholangitis study combines topics in areas such as Malignancy, Inflammatory bowel disease, Cholangiography, Ulcerative colitis and Colorectal cancer. His Primary biliary cirrhosis study incorporates themes from Bilirubin, Autoimmune hepatitis, Autoimmune disease and Transplantation. His Ursodeoxycholic acid research incorporates elements of Placebo, Clinical trial, Chemotherapy and Bile acid.
Keith D. Lindor focuses on Internal medicine, Gastroenterology, Primary sclerosing cholangitis, Liver transplantation and Ursodeoxycholic acid. All of his Internal medicine and Cirrhosis, Liver disease, Primary biliary cirrhosis, Hepatology and Hazard ratio investigations are sub-components of the entire Internal medicine study. Keith D. Lindor combines subjects such as Bilirubin, Endocrinology and Placebo with his study of Primary biliary cirrhosis.
His work deals with themes such as Pharmacotherapy and Proportional hazards model, which intersect with Gastroenterology. His studies in Primary sclerosing cholangitis integrate themes in fields like Malignancy, Clinical trial, Inflammatory bowel disease, Ulcerative colitis and Colorectal cancer. Keith D. Lindor usually deals with Liver transplantation and limits it to topics linked to Clinical endpoint and Adverse effect.
Keith D. Lindor spends much of his time researching Internal medicine, Gastroenterology, Primary sclerosing cholangitis, Ursodeoxycholic acid and Liver transplantation. His Cirrhosis, Primary biliary cirrhosis, Proportional hazards model, Liver disease and Hazard ratio investigations are all subjects of Internal medicine research. His work on Cholestasis is typically connected to Obeticholic acid as part of general Gastroenterology study, connecting several disciplines of science.
The Primary sclerosing cholangitis study combines topics in areas such as Malignancy, Inflammatory bowel disease, Ulcerative colitis, Chronic liver disease and Colorectal cancer. In his research, Combination therapy is intimately related to Bile acid, which falls under the overarching field of Ursodeoxycholic acid. The various areas that Keith D. Lindor examines in his Liver transplantation study include Portal hypertension, Colitis, Guideline, Gallstones and Bile duct.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Leon A. Adams;James F. Lymp;Jenny St. Sauver;Schuyler O. Sanderson.
The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD
Paul Angulo;Jason M. Hui;Giulio Marchesini;Ellisabetta Bugianesi.
Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
Paul Angulo;Jill C. Keach;Kenneth P. Batts;Keith D. Lindor.
Primary Biliary Cirrhosis
Keith D. Lindor;M. Eric Gershwin;Raoul Poupon;Marshall Kaplan.
Nonalcoholic fatty liver disease
Leon A. Adams;Paul Angulo;Keith D. Lindor.
Canadian Medical Association Journal (2005)
Non-alcoholic fatty liver disease.
Paul Angulo;Keith D Lindor.
Journal of Gastroenterology and Hepatology (2002)
The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies.
Leon A. Adams;Schuyler Sanderson;Keith D. Lindor;Paul Angulo.
Journal of Hepatology (2005)
Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis.
Ariel E Feldstein;Ali Canbay;Paul Angulo;Makiko Taniai.
Immunoglobulin G4–Associated Cholangitis: Clinical Profile and Response to Therapy
Amaar Ghazale;Suresh T. Chari;Lizhi Zhang;Thomas C. Smyrk.
Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.
Keith D. Lindor;Kris V. Kowdley;E. Jenny Heathcote;M. Edwyn Harrison.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: